Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis

A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC. Between March 2005 and February 2011, 112 eli...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research and treatment 2013, 45(2), , pp.95-102
Main Authors: Lee, Dong Soo, Kang, Jin Hyoung, Lee, Chang Geol, Kim, Seoung Jun, Choi, Young Jin, Lee, Kyo Young, Kim, Yeon Sil
Format: Article
Language:English
Subjects:
Original
의약학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343
cites cdi_FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343
container_end_page 102
container_issue 2
container_start_page 95
container_title Cancer research and treatment
container_volume 45
creator Lee, Dong Soo
Kang, Jin Hyoung
Lee, Chang Geol
Kim, Seoung Jun
Choi, Young Jin
Lee, Kyo Young
Kim, Yeon Sil
description A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC. Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain. The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p
doi_str_mv 10.4143/crt.2013.45.2.95
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_254500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1406176228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343</originalsourceid><addsrcrecordid>eNpVUU1vEzEUtBCIhsKdE_KRyy7-3jUHpCgqtFKACgpXy-uPxnQ_UtsboL8eJ4ECkuX3LM_Me5oB4DlGNcOMvjIx1wRhWjNek1ryB2BBEOKVJFw8BAvMZVsRKdsT8CSlbwgJRhv8GJwQ2grWMrIAd5fR2WByGK_h5znuwk73MIzwUufgxpzg95A3cGl3ejTOwg_TWKXbWQ_TnI6PQfc9XLlyreeisdrj4mv4VffB6oNs3jh49iMXNTh5-N5lncoJ6Sl45HWf3LPf9RR8eXt2tTqv1h_fXayW68owInPVaepdwzXxVgvfCoyFMJgSJ1HjdCcEwk1jre46yxkrHW86wlvUcS-cp4yegpdH3TF6dWOCmnQ41OtJ3US1_HR1oQhnHKECfXOEbuducNaUnaPu1TaGQcefB-L_P2PYFJmdKrYiKdq_s7Zxup1dymoIyRR39OiKZQozJHAjCNlD0RFq4pRSdP5-DEZqn64q6ap9uopxRZTkhfLi3_XuCX_ipL8AbESjYA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1406176228</pqid></control><display><type>article</type><title>Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis</title><source>PubMed Central（OA）</source><creator>Lee, Dong Soo ; Kang, Jin Hyoung ; Lee, Chang Geol ; Kim, Seoung Jun ; Choi, Young Jin ; Lee, Kyo Young ; Kim, Yeon Sil</creator><creatorcontrib>Lee, Dong Soo ; Kang, Jin Hyoung ; Lee, Chang Geol ; Kim, Seoung Jun ; Choi, Young Jin ; Lee, Kyo Young ; Kim, Yeon Sil</creatorcontrib><description>A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC. Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain. The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p&lt;0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS. The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.</description><identifier>ISSN: 1598-2998</identifier><identifier>EISSN: 2005-9256</identifier><identifier>DOI: 10.4143/crt.2013.45.2.95</identifier><identifier>PMID: 23864842</identifier><language>eng</language><publisher>Korea (South): Korean Cancer Association</publisher><subject>Original ; 의약학</subject><ispartof>Cancer Research and Treatment, 2013, 45(2), , pp.95-102</ispartof><rights>Copyright © 2013 by the Korean Cancer Association 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343</citedby><cites>FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710968/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710968/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23864842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001778302$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Dong Soo</creatorcontrib><creatorcontrib>Kang, Jin Hyoung</creatorcontrib><creatorcontrib>Lee, Chang Geol</creatorcontrib><creatorcontrib>Kim, Seoung Jun</creatorcontrib><creatorcontrib>Choi, Young Jin</creatorcontrib><creatorcontrib>Lee, Kyo Young</creatorcontrib><creatorcontrib>Kim, Yeon Sil</creatorcontrib><title>Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis</title><title>Cancer research and treatment</title><addtitle>Cancer Res Treat</addtitle><description>A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC. Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain. The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p&lt;0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS. The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.</description><subject>Original</subject><subject>의약학</subject><issn>1598-2998</issn><issn>2005-9256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVUU1vEzEUtBCIhsKdE_KRyy7-3jUHpCgqtFKACgpXy-uPxnQ_UtsboL8eJ4ECkuX3LM_Me5oB4DlGNcOMvjIx1wRhWjNek1ryB2BBEOKVJFw8BAvMZVsRKdsT8CSlbwgJRhv8GJwQ2grWMrIAd5fR2WByGK_h5znuwk73MIzwUufgxpzg95A3cGl3ejTOwg_TWKXbWQ_TnI6PQfc9XLlyreeisdrj4mv4VffB6oNs3jh49iMXNTh5-N5lncoJ6Sl45HWf3LPf9RR8eXt2tTqv1h_fXayW68owInPVaepdwzXxVgvfCoyFMJgSJ1HjdCcEwk1jre46yxkrHW86wlvUcS-cp4yegpdH3TF6dWOCmnQ41OtJ3US1_HR1oQhnHKECfXOEbuducNaUnaPu1TaGQcefB-L_P2PYFJmdKrYiKdq_s7Zxup1dymoIyRR39OiKZQozJHAjCNlD0RFq4pRSdP5-DEZqn64q6ap9uopxRZTkhfLi3_XuCX_ipL8AbESjYA</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Lee, Dong Soo</creator><creator>Kang, Jin Hyoung</creator><creator>Lee, Chang Geol</creator><creator>Kim, Seoung Jun</creator><creator>Choi, Young Jin</creator><creator>Lee, Kyo Young</creator><creator>Kim, Yeon Sil</creator><general>Korean Cancer Association</general><general>대한암학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope></search><sort><creationdate>20130601</creationdate><title>Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis</title><author>Lee, Dong Soo ; Kang, Jin Hyoung ; Lee, Chang Geol ; Kim, Seoung Jun ; Choi, Young Jin ; Lee, Kyo Young ; Kim, Yeon Sil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Original</topic><topic>의약학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Dong Soo</creatorcontrib><creatorcontrib>Kang, Jin Hyoung</creatorcontrib><creatorcontrib>Lee, Chang Geol</creatorcontrib><creatorcontrib>Kim, Seoung Jun</creatorcontrib><creatorcontrib>Choi, Young Jin</creatorcontrib><creatorcontrib>Lee, Kyo Young</creatorcontrib><creatorcontrib>Kim, Yeon Sil</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Dong Soo</au><au>Kang, Jin Hyoung</au><au>Lee, Chang Geol</au><au>Kim, Seoung Jun</au><au>Choi, Young Jin</au><au>Lee, Kyo Young</au><au>Kim, Yeon Sil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis</atitle><jtitle>Cancer research and treatment</jtitle><addtitle>Cancer Res Treat</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>45</volume><issue>2</issue><spage>95</spage><epage>102</epage><pages>95-102</pages><issn>1598-2998</issn><eissn>2005-9256</eissn><abstract>A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC. Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain. The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p&lt;0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS. The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.</abstract><cop>Korea (South)</cop><pub>Korean Cancer Association</pub><pmid>23864842</pmid><doi>10.4143/crt.2013.45.2.95</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1598-2998
ispartof Cancer Research and Treatment, 2013, 45(2), , pp.95-102
issn 1598-2998
2005-9256
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_254500
source PubMed Central（OA）
subjects Original
의약학
title Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A40%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20Survival%20in%20Patients%20with%20Advanced%20Non-squamous%20Non-small%20Cell%20Lung%20Cancer:%20Validating%20the%20Extent%20of%20Metastasis&rft.jtitle=Cancer%20research%20and%20treatment&rft.au=Lee,%20Dong%20Soo&rft.date=2013-06-01&rft.volume=45&rft.issue=2&rft.spage=95&rft.epage=102&rft.pages=95-102&rft.issn=1598-2998&rft.eissn=2005-9256&rft_id=info:doi/10.4143/crt.2013.45.2.95&rft_dat=%3Cproquest_nrf_k%3E1406176228%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-ba3fe75a2fda6f861166c132e907eab660177ddabbd5447dd57b2580b5f6ef343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1406176228&rft_id=info:pmid/23864842&rfr_iscdi=true